PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On August 8, 2017, Protagonist Therapeutics, Inc. reported its financial results for the quarter ended June30, 2017. A copy of the press release titled “Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights,” is furnished to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 2.02. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
Description |
|
99.1 |
Press release, dated August8, 2017, titled “Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights.” |
The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Protagonist Therapeutics, Inc ExhibitEX-99.1 2 ptgx8-kq2ex991.htm EXHIBIT 99.1 Exhibit Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business HighlightsWorldwide co-development agreement with Janssen for PTG-200 brings $50M upfront and potentially up to $940M in milestonesQ2 cash balance of $64.5M – Cash to middle of 2019Newark,…To view the full exhibit click here
About PROTAGONIST THERAPEUTICS, INC. (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.